However, androgen deprivation therapy (ADT) [16], designed to directly target AR-expressing prostate epithelial tumor cells through either antagonizing the AR or inhibiting androgen production, ultimately fails in almost all of patients, leading to the development of castration-resistant PCa (CRPC), an incurable disease [7, 11]. This evidence concerns the gene AR and posterior cortical atrophy.